Presentations

OBRI Presentations from 2008 to 2017

Please note that prior to 2013, the OBRI was referred to as the Ontario Biologics Research Initiative.

CRA 2017:

Couto, S., Cesta, A., Ahluwalia, V., Haaland, D., Karasik, A., Sebaldt, R., Thorne, C., Bombardier, C. Automated Data Extraction from Electronic Medical Records in Rheumatology – An Ontario Best Practices Research Initiative Pilot Project. CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Movahedi, M., Cesta, A., Li, X., Bombardier, C., and OBRI Investigators. Collection of Anti-Rheumatic Medication Data From Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort (OBRI). CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Joshi, R., Kuriya, B., Movahedi,  M., Rampakakis, E., Cesta, A., Li, Couto, S., Sampalis, J.S., Bombardier, C., and OBRI Investigators. High disease activity is a predictor of depression and persistent depression in early rheumatoid arthritis – results from the Ontario Best Practices Research Initiative (OBRI).  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Lau, A., Thorne, C., Movahedi, M., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Rampakakis, E., Bombardier, C., and OBRI investigators.  Impact of Concomitant Use of Disease Modifying Antirheumatic Drugs and Methotrexate Administration Route on Durability of Biologic Treatment – Results from the Ontario Best Practice Research Initiative (OBRI) Cohort.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Tatangelo, M., Li, X., Cesta, A., Movahedi, M., Bombardier, C., Tomlinson, G.  Multiple Statistical Imputation of Missing Data in a Real World Clinical Cohort Increased Sample Size and Power with Minimal Deviations Enhancing the Clinical Research Potential of the Observational Dataset.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Fullerton, L., Brooks, S., Sweezie, R., Ahluwalia, V., Bombardier, C., Gagliardi, A.R. Patient, Rheumatologist, and Extended Role Practitioner (ERP) Perspectives on the Implementation and Impact of an Allied Health Rheumatology Triage Initiative in Ontario Rheumatology Clinics.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Brooks, S., Bombardier, C., Bell, M., Cesta, A., Fullerton, L., Karasik, A., Kendzerska, T., Sweezie, R., Widdifield, J., Ahluwalia, V. The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Ahluwalia, V., Movahedi, M., Rampakakis, E., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Bombardier, C., and OBRI investigators. Predictors of patient reported decision to discontinue Anti-Rheumatic Medication in Rheumatoid Arthritis Patients – Data from a Rheumatoid Arthritis Cohort  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

 

ACR 2016:

Ahluwalia V, Movahedi M, Rampakakis E, Cesta A, Li X, Sampalis J, Bombardier C, OBRI Investigators. Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Results from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Washington DC. Nov. 15, 2016. (Oral Presentation)

Thorne C, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis J, Bombardier C. Concomitant Use of Oral vs. Subcutaneous Methotrexate at Biologic Initiation: a Comparison of Biologic Treatment Survival in the Ontario Best Practice Research Initiative (OBRI) Cohort. ACR Annual Scientific Meeting, Washington, DC. Nov. 15, 2016. (Poster Presentation)

Brooks S, Bombardier C, Bell M, Cesta A, Kendzerska,T, Sweezie R, Widdifield J, Fullerton L, Ahluwalia V, Karasik A. The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario. ACR Annual Scientific Meeting, Washington DC. Nov. 15, 2016. (Poster Presentation)

EULAR 2016:

Cesta A, Li X, Tatangelo M, Bombardier C, and OBRI Investigators. Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Lau A, Movahedi M, Tatangelo M, Bombardier C and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Cui K, Bombardier C, Tomlinson GA, and OBRI Investigators. Contributions of Social Determinants of Health on Remission in Rheumatoid Arthritis. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C. and OBRI Investigators. Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from an Ontario Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016. (Supplementary Publication)

Roehkar G, Movahedi M, Pope JE, Bombardier C. Durability of First Biologic is Not Influenced by Initial/Early DAS28. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016. (Supplementary Publication)

CRA 2016:

Lau A, Movahedi M, Tatangelo M, Bombardier C and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C and OBRI investigators. Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from an Ontario Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Thorne C, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis J, Bombardier C. Concomitant Use of Oral vs. Subcutaneous Methotrexate at Biologic Initiation:  a Comparison of Biologic Treatment Survival in the Ontario Best Practice Research Initiative (OBRI) Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Keystone E, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C and OBRI Investigators. What is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? An Analysis from a Prospective, Observational Registry. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Tatangelo M, Paterson M, Tomlinson GA, Bansback N, Widdifield J, Gomes T, Bombardier C. Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Cui K, Bombardier C, Tomlinson GA, and OBRI Investigators. Contributions of Social Determinants of Health on Treatment Responses in Rheumatoid Arthritis Patients. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Kuriya B, Li X, Tomlinson GA, Keystone E, Bombardier C, and OBRI Investigators. Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Cesta A, Li X, Tatangelo M, Bombardier C and OBRI Investigators. Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

ACR 2015:

Lau A, Movahedi M, Tatangelo M, Bombardier C, and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying  Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C, and OBRI investigators. Treatment patterns in rheumatoid arthritis after methotrexate:  Data from an Ontario Rheumatoid Arthritis Cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Tatangelo M, Paterson M, Tomlinson GA, Bansback N, Widdifield J, Gomes T, Bombardier C. Temporal trends in drug prescription, utilization and costs among Rheumatoid Arthritis (RA) patients show wide regional variation despite universal drug coverage. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Oral Presentation)

Tatangelo M, Tomlinson GA, Kuriya B, Bombardier C. Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Cui K, Bombardier C, Tomlinson GA, and the OBRI Investigators. Contributions of social determinants of health on treatment responses in Rheumatoid Arthritis patients. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Kuriya B, Li X, Tomlinson GA, Keystone EC, Bombardier C, and OBRI Investigators. Predictors of disease relapse and recapture of remission following relapse in an Ontario rheumatoid arthritis population. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Oral Presentation)

Kelkar A, Cesta A, Li X, Bombardier C, and the OBRI Investigators. Characterization of patient reported pain medication in early Vs. established Rheumatoid Arthritis. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Keystone E, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C, OBRI Investigators. What is the rate of primary and secondary failure of anti-TNF in RA patients? An analysis from a prospective, observational registry. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Fullerton L., Cesta A., Hofstetter C., Bombardier C.  and the OBRI Investigators. Patient priorities in RA research: An exploration of perspectives from those enrolled in a Canadian RA clinical cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Cesta A, Li X, Tatangelo M, Bombardier C, and  the OBRI Investigators. Attrition and participant characteristics in a Rheumatoid Arthritis cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

EULAR 2015:

Cui K, Jacob B, Widdifield J, Pope J, Kuriya B, Akhavan P, Bombardier C. Characteristics of rheumatoid arthritis patient with and without cardiovascular disease – Data from the Ontario Best Practices Research Initiative. EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Kelkar A, Cesta A, Li X, Bombardier C. Characterization of patient-reported pain medications in rheumatoid arthritis – Results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Tatangelo M, Tomlinson G, Kuriya B, Bombardier C. Disease activity patterns in rheumatoid arthritis in the first 3 years of follow up in usual care: Markov modelling shows rapid improvement in DAS28 states in 1st year followed by stable states in the last 2 years – Results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson M, Abrahamowicz M, Kuriya B, Tomlinson G, Tatangelo M, Thorne C, Pope J, Luo J, Bombardier C. Comparisons of reporting and level of agreement of co-morbidities ascertained from rheumatologists, patients, and health administrative data: A data linkage study among patients with rheumatoid arthritis.. EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

CRA 2015:

Collins S, McKeown T, Heslegrave R, Bombardier C. Pilot evaluation of an electronic research platform supporting e-consent. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Cui K, Jacob B, Widdifield J, Pope J, Li X, Kuriya B, Akhavan P, Bombardier C. Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients – Data from the Ontario Best Practices Research Initiative (OBRI). CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Fullerton L, Cesta A, Hofstetter C, Bombardier C. Patient priorities in rheumatoid arthritis research – An exploration of patient perspectives from those enrolled in the Ontario Best Practices Research Initiative (OBRI) clinical registry. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Gosio J, Bombardier C, Jacob B, Li X, Paterson M, Widdifield J. The generalizability of the Ontario Best Practices Research Initiative to the Ontario rheumatoid arthritis population and general population. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Guo N, Jacob B, Li X, Couto S, Keystone E, Bombardier C. Disease activity in moderate rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Harold A, Collins S, Bombardier C. Clinical rheumatology research in the digital age: Consent and governance challenges. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Jacob B, Li X, Cesta A, Kuriya B, Keystone E, Bombardier C. Comparison of patient self-reported and physician reported rheumatoid arthritis medication use – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Kelkar A, Li X, Cesta A, Bombardier C. Characterization of patient reported pain medication in rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative (OBRI). CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Kuriya B, Li X, Jacob B, Widdifield J, Pope J, Bombardier C. Time-to-remission, time-to-relapse and disease severity at the time of relapse in RA – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen W, Ahluwalia V, Karasik A, Bombardier C. Comparison of medication use in rheumatoid arthritis patients between university and community settings – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Rohekar G, Jacob B, Pope J, Bombardier C. Durability of first biologic is not influenced by initial/early DAS28. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Derivation and comparison utility scores for economic evaluation in large datasets: Modeling patient level EQ-5D using the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Tatangelo M, Li X, Cesta A, Paterson M, Widdifield J, Bombardier C. Harnessing the power of administrative data linkage: Results from the Ontario Best Practices Research Initiative clinical linked cohort. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

ACR 2014:

Cui K, Jacob B, Pope J, Widdifield J, Li X, Kuriya B, Akhavan P, Bombardier C. Characteristics of rheumatoid arthritis patients with and without cardiovascular diseases – Data from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Jacob B, Li X, Cesta A, Kuriya B, Keystone E, Bombardier C. Comparison of Patient Self-Reported and Physician Reported Rheumatoid Arthritis Medication Use – Results from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Kuriya B, Li X, Jacob B, Widdifield J, Pope J, Bombardier C. Time-to-remission, time-to-relapse in RA – Results from the Ontario Best Practice Research Initiative (OBRI). ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Oral Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen W, Ahluwalia, Karasik A, Bombardier C. Comparison of medication use in rheumatoid arthritis patients between university and private settings – Results from the Ontario Best Practice Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Rohekar G, Jacob B, Pope J, Bombardier C. Durability of first biologic is not influenced by initial/early DAS28. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Widdifield J, Bombardier C, Thorne C, Jaakkimainen L, Paterson M, Bernatsky S, Young J, Wing L, Ivers N, Butt D, Poon V, Ahluwalia V, Tu K. A novel approach to assess wait times to rheumatologists. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Widdifield J, Bombardier C, Young J, Ivers N, Jaakkimainen L, Bernatsky S, Paterson M, Thorne C, Akhavan P, Butt D, Ahluwalia V, Tu K. Quality of primary care management of patients with and without rheumatoid arthritis. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Oral Presentation)

TGRI 2014:

Cui K, Jacob B, Widdifield J, Pope J, Li X, Kuriya B, Akhavan P, Bombardier C. Prevalence and characteristics of cardiovascular diseases in rheumatoid arthritis patients – Data from the Ontario Best Practice Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Gosio J, Bombardier C, Jacob B, Li X, Widdifield J. The generalizibility of the Ontario Best Practices Research Initiative to the Ontario rheumatoid arthritis population and general population. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Guo N, Jacob B, Li X, Couto S, Keystone E, Bombardier C. Disease activity in moderate rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen B, Ahuluwalia V, Karasik A, Bombardier C. Comparison of patients in different rheumatology settings – Results from the Ontario Best Practice Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Creation and comparison of a quality of life reference set using utility from a large observational cohort: Results from the Ontario Best Practices Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

EULAR 2014:

Mittoo S, Jacob B, Bombardier C. Lung disease among rheumatoid arthritis patients – Results from Ontario Biologics Research Initiative (OBRI). EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Hazlewood G, Jacob B, Akhavan P, Bombardier C. Methotrexate parenteral administration versus oral delivery: A comparison of treatment survival using Ontario Best Practice Research Initiative (OBRI) cohort. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Jacob B, Tomlinson GA, Akhavan P, Bombardier C. Cigarette smoking and RA disease activity and health related QOL: Results from Ontario Best Practices Initiative. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Widdifield J, Young, Bombardier C, Jaakkimainen RL, Butt D, Ivers N, Bernatsky S, Paterson JM, Thorne C, Ahluwalia V, Tomlinson G, Tu K. Identifying Patients With Rheumatoid Arthritis in Primary Care Electronic Medical Records. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

CAREB 2014:

Heslegrave R, Harold A, Knoppers BM, Zawati M, Bombardier C. Longitudinal Clinical Research in the Digital Age: Consent, Governance, and Ethics Challenges. Canadian Association of Research Ethics Boards (CAREB) 2014 Conference. Montreal, Quebec, April 25, 2014. (Oral Presentation)

CRA 2014:

Bombardier C, Heslegrave R, Collins S, Baron M, Zawati M, Taillefer S, Knoppers BM. Electronic Consent Processes for Rheumatology Research (11). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Cesta A, Li X ,  Couto S, Jacob B, Bombardier C. Adherence to rheumatoid arthritis medications and the reasons for non-compliance: results from OBRI (147). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Jacob B, Tomlinson GA, Akhavan P, Bombardier C. Cigarette smoking and disease activity in rheumatoid arthritis patients: Results from Ontario Best Practice Research Initiative (OBRI). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Kelkar A, Couto S, Jacob B, Bombardier C. Use of MEDSCHECK program among RA patients – results from OBRI (148).Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Nguyen J, Jacob B, Akhavan P, Bombardier C. Methods used in standardizing drug names: experience from OBRI study (146). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Tatangelo M and Bombardier C. Economic evaluation using observational data: A scoping review (187). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from OBRI. Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

ACR 2013:

Akhavan P, Jacob B, Keystone E, Li X, Thorne C and Bombardier C. Factors affecting the discrepancy between physician and patient global  assessment of disease activity in early and established rheumatoid arthritis  patients – Results from OBRI. San Diego, CA. October 25-30, 2013. (Poster Presentation)

Akhavan P, Jacob B, Fortin PR, Tomlinson GA and Bombardier C. Predictive validity of low disease activity using patient reported measures on long term outcomes in patients with early rheumatoid arthritis – results from Study of New Onset Rheumatoid Arthritis and OBRI. San Diego CA, October 25-30, 2013. (Oral Presentation)

Kuriya B, Jacob B, Widdifield J, Li X, Bombardier C. How often are core variables reported to calculate common Disease Activity Scores measured in routine care of rheumatoid arthritis patients? San Diego CA, October 25-30, 2013. (Poster Presentation)

Nadarajah T, Jacob B, Akhavan P, Kuriya B. Keystone E, Bombardier C. Does age at disease onset influence disease activity and function in rheumatoid arthritis patients? Results from the OBRI registry. San Diego, CA. October 25-30, 2013. (Oral Presentation)

Tatangelo M, Tomlinson G, and Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from OBRI. San Diego, CA. October 25-30, 2013. (Poster Presentation)

Widdifield J, Paterson JM, Bernatsky S, Kuriya B, Thorne C, Hollands S, Bombardier C. All-cause mortality for patients with Rheumatoid Arthritis (RA) in a universal public health care system: Results from the ORAD. San Diego, CA. October 25-30, 2013. (Oral Presentation)

TGRI 2013:

Tatangelo M, Tomlinson G, Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from the Ontario Best Practices Research Initiative. 2013 TGRI Annual Research Day, Toronto, ON.

CRA 2013:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne C, Ivers N, Jaakkimainen L, Ahluwalia V, Bombardier C. Epidemiology of Rheumatoid Arthritis in a universal public health care system: Results from the Ontario RA administrative database (ORAD) (11). Presented at the 2013 CRA Annual Scientific Meeting, Ottawa, ON. Feb 14-16th, 2013. (Oral Presentation)

ACR 2012:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Ivers N, Butt D. Potential barriers that limit timely access to rheumatologists among patients with early rheumatoid arthritis in a universal public health care system. ACR Annual Scientific Meeting 2012. (Oral presentation)

EULAR 2012:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne C, Ivers N, Butt D. Rheumatoid Arthritis (RA) care: Geographic disparities and impact of primary care physicians on access to rheumatologists. EULAR Annual Meeting, Berlin, June 6-9, 2012. (Poster Presentation)

CAPT 2011:

Bombardier C.  Biologic Agents – View on Benefit/Safety. (Oral Presentation)

CRA 2011:

Thorne C, Cividino A, Pope J, Bernatsky S, Li X, Ashoor H, Cesta A, Bombardier C. Disease activity in patients prescribed biologics in Ontario: Results from the Ontario Biologics Research Initiative (OBRI) cohort (p.133).  Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. Demyelinating events in seniors with Rheumatoid Arthritis (RA): A population-based study (p. 77). Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. The incidence of herpes zoster in seniors with rheumatoid arthritis: A population-based study (p. 78). Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

EULAR 2011:

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Cividino A, Thorne JC, Pope J, Bombardier C. Hospitalization for acute hepatotoxicity among seniors with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl3):453. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Cividino A, Thorne JC, Pope J, Bombardier C. Use of non-steroidal anti-inflammatory drugs, selective cyclo-oxygenase inhibitors (coxibs), proton pump inhibitors and H2-receptor antagonists and risk of serious infections among seniors with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl 3):453. (Poster Presentation)

ACR 2010:

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Pope J, Thorne C, Cividino A. Demyelinating events in seniors with rheumatoid arthritis. Arthritis Rheum 2010:62(Suppl). (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Pope JE, Thorne C, Cividino A. Invasive fungal infections in seniors with rheumatoid arthritis: A population-based study from the Ontario Biologics Research Initiative. Arthritis Rheum 2010: 62(Suppl); S313. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Pope JE, Thorne C, Cividino A. The incidence of herpes zoster in seniors with rheumatoid arthritis. Arthritis Rheum 2010: 62(Suppl); S341. (Poster presentation)

CADTH 2010:

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne JC, Cividino A, Bombardier C.  Under utilization of Disease Modifying Antirheumatic Drugs (Dmards) in Early Rheumatoid Arthritis (ERA): A population-based study from the Ontario Biologics Research Initiative. Comparing rheumatology care with primary care. Canadian Agency for Drugs and Technologies in Health. (Poster Presentation)

CAPT 2010:

Bernatsky S, Paterson M, Hux J, Thorne C, Cividino A, Pope J, Bombardier C. RA and risk of serious infections: A nested case-control study: Update from the OBRI administrative database analysis. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Under utilization of Disease Modifying Antirheumatic Drugs (Dmards) in Early Rheumatoid Arthritis (ERA): A population-based study from the Ontario Biologics Research Initiative. Comparing rheumatology care with primary care. Canadian Agency for Drugs and Technologies in Health. (Poster Presentation)

Bombardier C, Thorne C, Cividino A, Widdifield J, Pope J, Bernatsky S, Ashoor H, Cesta A, Li X, Paterson M. Baseline characteristics & preliminary efficacy results of patients receiving biologic and traditional DMARDs in Ontario. (Poster Presentation)

CRA 2010:

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Serious fungal infections in seniors with Rheumatoid Arthritis (RA): A population based study. Results of the OBRI administrative database analysis. J Rheumatol 2010; 37(6): 1279-79. (Poster Presentation)

Bernatsky S, Paterson M, Widdifield J, Thorne C, Pope J, Cividino A, Bombardier C. RA and risk of serious infections: A nested case-control study. Results from the Ontario Biologics Research Initiative (p. 14). J Rheumatol 2010; 37(6): 1279-79. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Under utilization of Dmards in early rheumatoid arthritis: A population-based study from the Ontario Biologics Research Initiative. Comparing Rheumatology Care With Primary Care (p. 228). J Rheumatol 2010; 37(6): 1348-48. (Poster Presentation)

Bombardier C, Thorne C, Cividino A, Widdifield J, Pope J, Bernatsky S, Ashoor H, Cesta A, Li X, Paterson M. Baseline characteristics and preliminary efficacy results of patients receiving biologic and traditional Disease Modifying Anti-Rheumatic Drugs (Dmards) in Ontario: Results From The OBRI (p.17). J Rheumatol 2010; 37(6): 1280-80. (Poster Presentation)

Pease C, Pope J, Truong D, Bombardier C, Widdifield J, Thorne C, Haraoui B, Psaradellis F, Sampalis J, Bonner A. Comparison Of Anti-TNF Treatment Initiation In RA Databases Demonstrates Wide Country Variability In Patient Parameters At Initiation Of Anti-TNF Therapy (p.90). J Rheumatol 2010; 37(6): 1304-04.

Widdifield J, Thorne C, Hofstetter C, Lyddiatt A, Pugh P, Frank P, Bombardier C. Elevating Patients’ Knowledge On The Process To Access Publicly Funded Biologic Therapies: Benefits Of Collaborative Research Efforts (p. 229). J Rheumatol 2010; 37(6): 1348-49. (Poster Presentation)

CRC 2010:

Bombardier C. The Ontario Biologics Research Initiative (OBRI): An innovative platform For real-world drug surveillance and evidence-based practice indicators. (Poster Presentation)

EULAR 2010:

Bernatsky S, Widdifield J, Paterson M, Pope J, Thorne C, Bombardier C. Complicated herpes zoster infections in seniors with RA. Ann Rheum Dis 2010; 69(S3):675. (Poster Presentation)

Bernatsky S, Paterson M, Widdifield J, Pope J, Thorne C, Cividino A, Bombardier C. Rheumatoid arthritis and risk of serious infections: A nested case-control study from the Ontario Biologics Research Initiative. Ann Rheum Dis 2010; 69(S3): 495. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Serious fungal infection in seniors with rheumatoid arthritis. Ann Rheum Dis 2010; 69(S3):675. (Poster Presentation)

Bernatsky S, Widdifield J, Paterson M, Cividino A, Pope J, Thorne C, Bombardier C. Under-utilization of DMARDS in seniors with early RA. Ann Rheum Dis 2010; 69(Suppl3):93. (Poster Presentation)

ACR 2009:

Bernatsky S, Paterson M, Thorne C, Cividino A, Pope J, Widdifield J, Bombardier C. Predictors of serious infections in seniors with Rheumatoid Arthritis (RA): Results of the OBRI administrative database analysis. Arthritis Rheum 2009;60 Suppl 10:720. (Poster Presentation)

CADTH 2009:

Bernatsky S, Bombardier C, Cividino A, Hux J, Paterson M, Pope J, Thorne JC. An evaluation of the potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. (Poster Presentation)

CAPT 2009:

Bernatsky S, Paterson M, Bhamani A, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. Disease-Modifying Anti-Rheumatic Drug (DMARD) exposures and serious infections in seniors with Rheumatoid Arthritis (RA): A nested case-control study. Can J Clin Pharmacol 2009;16(1).

Bernatsky S, Bombardier C, Bhamani A, Cividino A, Hux J, Paterson M, Pope J, Thorne JC. Tuberculosis (TB) in a population-based cohort of seniors with Rheumatoid Arthritis (RA). Can J Clin Pharmacol 2009;16(1). (Poster Presentation)

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, et al. Use of administrative data to determine the potential effects of a national consensus statement on optimal early Rheumatoid Arthritis (RA) treatment in persons >65. Can J Clin Pharmacol 2009;16(1).

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, et al. Utilization of Biologic Response Modifying Drugs (BRMs) by Ontario rheumatology specialists. Can J Clin Pharmacol 2009;16(1). (Poster Presentation)

Bernatsky S, Bombardier C, Paterson JM, Hux J, Cividino A, Pope J, Thorne C. An evaluation of the potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. J Rheumatol 2009; 36(11): 2589-90.

Bernatsky S, Paterson JM, Bhamani A, Hux J, Cividino A, Bombardier C, Pope J, Thorne C. Medication exposures and serious infections in a population-based cohort of older individuals with Rheumatoid Arthritis (RA). J Rheumatol 2009; 36(11): 2590-90. (Poster Presentation)

Bernatsky S, Paterson M, Hux J, Cividino A, Thorne C, Bombardier C, Pope J. Serious infections in a population-based cohort of older individuals with rheumatoid arthritis. J Rheumatol 2009; 36(11): 2565-65. (Poster Presentation)

Bombardier C, Paterson JM, Zagorski B, Hux J, Bernatsky S, Cividino A, Pope J, Thorne C. Use of biologic response modifying drugs by Ontario rheumatology specialists: 2008 Update. J Rheumatol 2009; 36(11): 2590. (Poster Presentation)

Bombardier C, Bernatsky S, Cividino A, Paterson M, Pope J, Thorne C, Widdifield J, Li X. Baseline characteristics of patients receiving biologic and DMARD therapy in Ontario: Results From the Ontario Biologics Research Initiative. J Rheumatol 2009; 36(11): 2565-66. (Poster Presentation)

EULAR 2009:

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. An Evaluation of the Potential Effects of a National Consensus Statement on Optimal Treatment of Early Rheumatoid Arthritis in Ontario. Ann Rheum Dis 2009; 68(S3):549.

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Widdifield J, Bombardier C. Markers of Disease Activity and Corticosteroids Predict Serious Infection in Older Individuals With RA. Ann Rheum Dis 2009; 68(S3):132.

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. Tuberculosis In A Population-Based Cohort Of Seniors With RA. Ann Rheum Dis 2009; 68(S3):568.

Bombardier C, Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Widdifield J. Baseline Characteristics Of Patients Receiving Biologic And DMARD Therapy In Ontario: Results From The Ontario Biologics Research Initiative. Ann Rheum Dis 2009; 68(S3); 233.

ACR 2008:

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne C, Bombardier C. Serious Infections In A Population-Based Cohort Of Older Individuals With Rheumatoid Arthritis. Arthritis and Rheumatism 2008; 58(9): S270-S270.

CRA 2008:

Bombardier C, Ciurea I, English J, Wilkins A. An innovative approach to practice based post-marketing surveillance of rheumatoid arthritis using an established patient surveillance system: Results of a feasibility study. J Rheumatol 2008; 35(6):1196-97.

Bombardier C, Ciurea I, English J, Wilkins A. Characteristics of patients with rheumatoid arthritis who are members of the medic alert system in Ontario. J Rheumatol 2008; 35(6):1197-97.

Bombardier C, English J, Thorne C, Cividino A, Pope J. A qualitative study to determine best methods for post-marketing surveillance in usual rheumatology care in Ontario. J Rheumatol 2008; 35(6):1199-99.